WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

Search

Compass Pathways Plc ADR

Closed

2.83 -7.82

Overview

Share price change

24h

Current

Min

2.81

Max

3.08

Key metrics

By Trading Economics

Income

-4.4M

-43M

EPS

-0.63

Employees

166

EBITDA

513K

-41M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+533.33% upside

Dividends

By Dow Jones

Next Earnings

7 May 2025

Market Stats

By TradingEconomics

Market Cap

-83M

259M

Previous open

10.65

Previous close

2.83

Technical Score

By Trading Central

Confidence

Bullish Evidence

Compass Pathways Plc ADR Chart

Past performance is not a reliable indicator of future results.

Related News

4 Feb 2025, 18:52 UTC

Major Market Movers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

Peer Comparison

Price change

Compass Pathways Plc ADR Forecast

Price Target

By TipRanks

533.33% upside

12 Months Forecast

Average 17.67 USD  533.33%

High 45 USD

Low 9 USD

Based on 10 Wall Street analysts offering 12 month price targets forCompass Pathways Plc ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

2.91 / 3.105Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Compass Pathways Plc ADR

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.